A clinical trial of dual EZH1/2 (polycomb repressive complex 2 subunits) inhibitor: Phase I investigator-initiated study in pediatric, adolescent and young adult patient with malignant solid tumors (ELEPHANT trial)
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Valemetostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms ELEPHANT trial
- Sponsors Daiichi Sankyo Company
Most Recent Events
- 12 Jul 2022 New trial record
- 07 Jun 2022 According to the trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology, enrollment into the dose escalation cohort was completed.
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology.